Mahesan Subramaniam: Scientists Develop Antibody to Block Epstein-Barr Virus Infection
Mahesan Subramaniam, Co-Founder of United Health Tourism, posted on LinkedIn:
“Scientists created an antibody that can eradicate an infection that affects 95% of the global population.
The Epstein-Barr virus (EBV) is one of the world’s most pervasive pathogens, infecting nearly 95% of humans and persisting for life.
While widely known for causing mononucleosis, EBV is also a primary driver of several cancers, including lymphomas, and has been linked to severe neurological and chronic conditions.
Scientists at Fred Hutch Cancer Center have now achieved a significant breakthrough by developing human monoclonal antibodies designed to block the virus’s entry into human immune cells.
By targeting specific proteins the virus uses to attach and invade, this new approach has successfully prevented infection in advanced laboratory models, offering a potential solution to a decades-old medical challenge.
This development is particularly critical for the more than 128,000 Americans who undergo organ or bone marrow transplants annually.
In these vulnerable patients, EBV can reactivate and trigger post-transplant lymphoproliferative disorder, a life-threatening form of cancer with few preventative options.
The researchers envision a future where high-risk individuals receive antibody infusions to neutralize the virus before it can cause harm.
Although human clinical trials are the next necessary step, this Discovery represents a major leap toward controlling a quietly dangerous virus that has eluded effective prevention since its discovery.”

Stay updated with Hemostasis Today.
-
Mar 27, 2026, 17:43Heghine Khachatryan: Persistent Risks of Venous Thromboembolism in Pregnancy and Postpartum
-
Mar 27, 2026, 17:39Lucie Tvrdá: Missing Data Could Themselves Be Used as Predictors of Stroke Outcomes
-
Mar 27, 2026, 17:31José Antonio García Erce: Update of NICE Recommendations On Blood Transfusion
-
Mar 27, 2026, 17:30Improving the Diagnosis and Care of Bleeding Disorders in Ecuador – WFH
-
Mar 27, 2026, 17:24Timo Siepmann: Does Stroke Origin Change How IV Thrombolysis Helps During Thrombectomy?
-
Mar 27, 2026, 17:19Ahmed Koriesh: Would You Start DAPT If the Patient Presents After 24 Hours?
-
Mar 27, 2026, 17:17Ifeanyichukwu Ifechidere: Understanding the Sensitivity and Specificity of D-Dimer
-
Mar 27, 2026, 17:15Wolfgang Miesbach: The Benefit with Hemophilia Rebalancing Agents Is Real, But So Are The Open Questions
-
Mar 27, 2026, 17:13Sheharyar Raza: Applying AI to Accelerate Big Data Research in Transfusion Medicine